![](/img/cover-not-exists.png)
Cost-Effectiveness of Ibrutinib and Rituximab for the Relapsed or Refractory Chronic Lymphocytic Leukemia in China
Yang, F, Kumar, A, Rojanasarot, S, Schommer, JC, Shao, RVolume:
21
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.04.198
Date:
May, 2018
File:
PDF, 77 KB
english, 2018